AU2008319122A1 - A novel alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production - Google Patents

Info

Publication number

AU2008319122A1

AU2008319122A1 AU2008319122A AU2008319122A AU2008319122A1 AU 2008319122 A1 AU2008319122 A1 AU 2008319122A1 AU 2008319122 A AU2008319122 A AU 2008319122A AU 2008319122 A AU2008319122 A AU 2008319122A AU 2008319122 A1 AU2008319122 A1 AU 2008319122A1

Authority

AU

Australia

Prior art keywords

amino

trifluoropentanamide

methyl

fluoro

reaction

Prior art date

2007-10-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• -1 acetamide compound Chemical class 0.000 title description 21
• 239000003112 inhibitor Substances 0.000 title description 20
• DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title description 16
• 238000004519 manufacturing process Methods 0.000 title description 9
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title description 8
• 238000000034 method Methods 0.000 claims description 63
• XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 claims description 40
• 208000024827 Alzheimer disease Diseases 0.000 claims description 27
• 238000011282 treatment Methods 0.000 claims description 25
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 15
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
• 239000008194 pharmaceutical composition Substances 0.000 claims description 12
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 11
• 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 10
• 208000010877 cognitive disease Diseases 0.000 claims description 7
• 201000010374 Down Syndrome Diseases 0.000 claims description 6
• 208000027061 mild cognitive impairment Diseases 0.000 claims description 6
• 241000124008 Mammalia Species 0.000 claims description 4
• 239000002671 adjuvant Substances 0.000 claims description 4
• 239000003085 diluting agent Substances 0.000 claims description 3
• 150000001875 compounds Chemical class 0.000 description 105
• 238000006243 chemical reaction Methods 0.000 description 89
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 81
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
• 239000000203 mixture Substances 0.000 description 63
• 210000004027 cell Anatomy 0.000 description 56
• 239000000243 solution Substances 0.000 description 53
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 46
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
• 239000007787 solid Substances 0.000 description 38
• 238000003556 assay Methods 0.000 description 29
• 210000004556 brain Anatomy 0.000 description 29
• 241000700159 Rattus Species 0.000 description 28
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
• 238000005481 NMR spectroscopy Methods 0.000 description 26
• 239000011541 reaction mixture Substances 0.000 description 25
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 24
• 238000004128 high performance liquid chromatography Methods 0.000 description 24
• 238000002360 preparation method Methods 0.000 description 22
• 239000002904 solvent Substances 0.000 description 21
• 235000012970 cakes Nutrition 0.000 description 20
• 239000010410 layer Substances 0.000 description 20
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
• 235000019439 ethyl acetate Nutrition 0.000 description 18
• 241001465754 Metazoa Species 0.000 description 17
• 239000003814 drug Substances 0.000 description 17
• 230000005764 inhibitory process Effects 0.000 description 17
• 239000002002 slurry Substances 0.000 description 17
• 102000014736 Notch Human genes 0.000 description 16
• 108010070047 Notch Receptors Proteins 0.000 description 16
• 239000002953 phosphate buffered saline Substances 0.000 description 16
• 239000000047 product Substances 0.000 description 16
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
• 230000002829 reductive effect Effects 0.000 description 15
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
• 229940079593 drug Drugs 0.000 description 14
• 239000012044 organic layer Substances 0.000 description 14
• IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 14
• 241000282414 Homo sapiens Species 0.000 description 13
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 13
• 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 12
• 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 12
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
• 238000013103 analytical ultracentrifugation Methods 0.000 description 12
• 108090000765 processed proteins & peptides Proteins 0.000 description 12
• 239000003981 vehicle Substances 0.000 description 12
• OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 11
• 241000699666 Mus <mouse, genus> Species 0.000 description 11
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
• 238000011534 incubation Methods 0.000 description 11
• 230000011664 signaling Effects 0.000 description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
• 201000010099 disease Diseases 0.000 description 10
• 230000000694 effects Effects 0.000 description 10
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
• 239000011734 sodium Substances 0.000 description 10
• OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 9
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 9
• 108090000790 Enzymes Proteins 0.000 description 9
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
• 230000031709 bromination Effects 0.000 description 9
• 238000005893 bromination reaction Methods 0.000 description 9
• JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 9
• 238000001035 drying Methods 0.000 description 9
• 229940088598 enzyme Drugs 0.000 description 9
• 230000006698 induction Effects 0.000 description 9
• 230000009467 reduction Effects 0.000 description 9
• KTZZIDWVKLDWBF-GSVOUGTGSA-N (2r)-2-azaniumyl-5,5,5-trifluoropentanoate Chemical compound [O-]C(=O)[C@H]([NH3+])CCC(F)(F)F KTZZIDWVKLDWBF-GSVOUGTGSA-N 0.000 description 8
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 8
• 230000027455 binding Effects 0.000 description 8
• 238000002474 experimental method Methods 0.000 description 8
• 239000012091 fetal bovine serum Substances 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 8
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
• 239000012071 phase Substances 0.000 description 8
• 108090000623 proteins and genes Proteins 0.000 description 8
• 229960001225 rifampicin Drugs 0.000 description 8
• 238000003756 stirring Methods 0.000 description 8
• AMDXQCHTJWVNGY-SECBINFHSA-N (2r)-2-[(4-chlorophenyl)sulfonylamino]-5,5,5-trifluoropentanamide Chemical compound FC(F)(F)CC[C@H](C(=O)N)NS(=O)(=O)C1=CC=C(Cl)C=C1 AMDXQCHTJWVNGY-SECBINFHSA-N 0.000 description 7
• 238000005160 1H NMR spectroscopy Methods 0.000 description 7
• YCWDOQVXUVNYLQ-UHFFFAOYSA-N 3-(3-fluoro-4-methylphenyl)-1,2,4-oxadiazole Chemical compound C1=C(F)C(C)=CC=C1C1=NOC=N1 YCWDOQVXUVNYLQ-UHFFFAOYSA-N 0.000 description 7
• SCJCDNUXDWFVFI-UHFFFAOYSA-N 4,4,4-trifluorobutanal Chemical compound FC(F)(F)CCC=O SCJCDNUXDWFVFI-UHFFFAOYSA-N 0.000 description 7
• FYLZPFSWVMMCQC-UHFFFAOYSA-N 5,5,5-trifluoropentanamide Chemical compound NC(=O)CCCC(F)(F)F FYLZPFSWVMMCQC-UHFFFAOYSA-N 0.000 description 7
• 206010067889 Dementia with Lewy bodies Diseases 0.000 description 7
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 7
• 201000002832 Lewy body dementia Diseases 0.000 description 7
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• 239000012267 brine Substances 0.000 description 7
• 239000000872 buffer Substances 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
• FXSRCLGHCVIZPP-QGZVFWFLSA-N (2r)-2-[(4-chlorophenyl)sulfonyl-[(4-cyano-2-fluorophenyl)methyl]amino]-5,5,5-trifluoropentanamide Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC1=CC=C(C#N)C=C1F FXSRCLGHCVIZPP-QGZVFWFLSA-N 0.000 description 6
• ZBKXTEJUTGXVJL-UHFFFAOYSA-N 3-[4-(bromomethyl)-3-fluorophenyl]-1,2,4-oxadiazole Chemical compound C1=C(CBr)C(F)=CC(C2=NOC=N2)=C1 ZBKXTEJUTGXVJL-UHFFFAOYSA-N 0.000 description 6
• KUQQONVKIURIQU-UHFFFAOYSA-N 3-fluoro-4-methylbenzonitrile Chemical compound CC1=CC=C(C#N)C=C1F KUQQONVKIURIQU-UHFFFAOYSA-N 0.000 description 6
• ZESZAIOGACKOMB-UHFFFAOYSA-N 4-(bromomethyl)-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1CBr ZESZAIOGACKOMB-UHFFFAOYSA-N 0.000 description 6
• 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 6
• 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 6
• 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 6
• KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
• 102100038494 Nuclear receptor subfamily 1 group I member 2 Human genes 0.000 description 6
• 108010001511 Pregnane X Receptor Proteins 0.000 description 6
• 108010036908 Presenilin-2 Proteins 0.000 description 6
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
• 102000003929 Transaminases Human genes 0.000 description 6
• 108090000340 Transaminases Proteins 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 230000002210 biocatalytic effect Effects 0.000 description 6
• 238000002425 crystallisation Methods 0.000 description 6
• 230000008025 crystallization Effects 0.000 description 6
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
• 239000000706 filtrate Substances 0.000 description 6
• 201000008319 inclusion body myositis Diseases 0.000 description 6
• 239000000543 intermediate Substances 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 229910052757 nitrogen Inorganic materials 0.000 description 6
• 239000003208 petroleum Substances 0.000 description 6
• 102000004169 proteins and genes Human genes 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 229910052938 sodium sulfate Inorganic materials 0.000 description 6
• 235000011152 sodium sulphate Nutrition 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 239000007858 starting material Substances 0.000 description 6
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 6
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
• QEYYZUYXOGLKSR-UHFFFAOYSA-N 5,5,5-trifluoro-2-oxopentanoic acid Chemical compound OC(=O)C(=O)CCC(F)(F)F QEYYZUYXOGLKSR-UHFFFAOYSA-N 0.000 description 5
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
• 239000007995 HEPES buffer Substances 0.000 description 5
• 241000282567 Macaca fascicularis Species 0.000 description 5
• 102000012412 Presenilin-1 Human genes 0.000 description 5
• 108010036933 Presenilin-1 Proteins 0.000 description 5
• 102000012419 Presenilin-2 Human genes 0.000 description 5
• 229940121773 Secretase inhibitor Drugs 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 229960000583 acetic acid Drugs 0.000 description 5
• 150000001408 amides Chemical class 0.000 description 5
• 229940024606 amino acid Drugs 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 238000001816 cooling Methods 0.000 description 5
• LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 238000004821 distillation Methods 0.000 description 5
• 230000014509 gene expression Effects 0.000 description 5
• 239000008103 glucose Substances 0.000 description 5
• 210000001853 liver microsome Anatomy 0.000 description 5
• 239000012452 mother liquor Substances 0.000 description 5
• 239000003960 organic solvent Substances 0.000 description 5
• 239000013612 plasmid Substances 0.000 description 5
• XUXNAKZDHHEHPC-UHFFFAOYSA-M sodium bromate Chemical compound [Na+].[O-]Br(=O)=O XUXNAKZDHHEHPC-UHFFFAOYSA-M 0.000 description 5
• 229940124530 sulfonamide Drugs 0.000 description 5
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
• DDGONUBYCHNUML-OAQYLSRUSA-N 4-[[[(2r)-1-amino-4-methyl-1-oxopentan-2-yl]-(4-chlorophenyl)sulfonylamino]methyl]-n-(2-methoxyethyl)benzamide Chemical compound C1=CC(C(=O)NCCOC)=CC=C1CN([C@H](CC(C)C)C(N)=O)S(=O)(=O)C1=CC=C(Cl)C=C1 DDGONUBYCHNUML-OAQYLSRUSA-N 0.000 description 4
• HEXKSBHTYDTPFG-UHFFFAOYSA-N 5,5,5-trifluoro-2-(1-phenylethylamino)pentanenitrile Chemical compound FC(F)(F)CCC(C#N)NC(C)C1=CC=CC=C1 HEXKSBHTYDTPFG-UHFFFAOYSA-N 0.000 description 4
• 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
• 108020004414 DNA Proteins 0.000 description 4
• 101710088194 Dehydrogenase Proteins 0.000 description 4
• 206010012289 Dementia Diseases 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• 239000005089 Luciferase Substances 0.000 description 4
• 108010076504 Protein Sorting Signals Proteins 0.000 description 4
• 241000283984 Rodentia Species 0.000 description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
• 229910000024 caesium carbonate Inorganic materials 0.000 description 4
• 229910052799 carbon Inorganic materials 0.000 description 4
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 4
• 125000000068 chlorophenyl group Chemical group 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 210000004748 cultured cell Anatomy 0.000 description 4
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
• ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
• 231100000414 gastrointestinal toxicity Toxicity 0.000 description 4
• 210000003494 hepatocyte Anatomy 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 208000002780 macular degeneration Diseases 0.000 description 4
• 238000001819 mass spectrum Methods 0.000 description 4
• 238000010907 mechanical stirring Methods 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 229920000136 polysorbate Polymers 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 229960005322 streptomycin Drugs 0.000 description 4
• 150000003456 sulfonamides Chemical class 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• UTBXDGYFBQOTLF-FOKYBFFNSA-N (2r)-5,5,5-trifluoro-2-[[(1r)-1-phenylethyl]amino]pentanamide;hydrochloride Chemical compound Cl.FC(F)(F)CC[C@H](C(N)=O)N[C@H](C)C1=CC=CC=C1 UTBXDGYFBQOTLF-FOKYBFFNSA-N 0.000 description 3
• FBKFDSUZBVDZIX-FFGDOFBPSA-N (4s)-4-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-acetamido-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-2-methylpropanoyl]amino]-3-[4-(phosphonomethyl)phenyl]propanoyl]amino]-3-(6-chloro-1h-indol-3-yl)propanoyl]amino]-5-[[1-[[(2s)-1-amino-4-meth Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NC(C)(C)C(=O)N[C@@H](CC=1C=CC(CP(O)(O)=O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=C(Cl)C=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)NC1(CC1)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(C)=O)C1=CC=CC=C1 FBKFDSUZBVDZIX-FFGDOFBPSA-N 0.000 description 3
• BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 3
• RCNTZYAQXVFCBQ-UHFFFAOYSA-N 3-fluoro-n'-hydroxy-4-methylbenzenecarboximidamide Chemical compound CC1=CC=C(C(N)=NO)C=C1F RCNTZYAQXVFCBQ-UHFFFAOYSA-N 0.000 description 3
• 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 3
• 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 3
• 102400000573 Amyloid-beta protein 40 Human genes 0.000 description 3
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 206010054949 Metaplasia Diseases 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 229930182555 Penicillin Natural products 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• 241000009328 Perro Species 0.000 description 3
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
• 102000015499 Presenilins Human genes 0.000 description 3
• 108010050254 Presenilins Proteins 0.000 description 3
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 206010064930 age-related macular degeneration Diseases 0.000 description 3
• 125000005219 aminonitrile group Chemical group 0.000 description 3
• 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 3
• FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 235000011089 carbon dioxide Nutrition 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 238000004090 dissolution Methods 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 210000001198 duodenum Anatomy 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 210000002950 fibroblast Anatomy 0.000 description 3
• 230000002496 gastric effect Effects 0.000 description 3
• 210000002175 goblet cell Anatomy 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
• 229910001629 magnesium chloride Inorganic materials 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000015689 metaplastic ossification Effects 0.000 description 3
• 230000003228 microsomal effect Effects 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 150000002825 nitriles Chemical class 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 229940049954 penicillin Drugs 0.000 description 3
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 3
• 230000036515 potency Effects 0.000 description 3
• 239000002287 radioligand Substances 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 3
• SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• 238000001228 spectrum Methods 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 238000010189 synthetic method Methods 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• QJDFHHHWSJMLQS-MRXNPFEDSA-N (2r)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(n'-hydroxycarbamimidoyl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC1=CC=C(C(=N)NO)C=C1F QJDFHHHWSJMLQS-MRXNPFEDSA-N 0.000 description 2
• GDTKAFYBAAISCN-AENDTGMFSA-N (2r)-2-amino-5,5,5-trifluoropentanamide;hydrochloride Chemical compound Cl.NC(=O)[C@H](N)CCC(F)(F)F GDTKAFYBAAISCN-AENDTGMFSA-N 0.000 description 2
• HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 2
• SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 2
• GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 2
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
• 238000004293 19F NMR spectroscopy Methods 0.000 description 2
• RDRZEPABDVDQAK-UHFFFAOYSA-N 3-[4-(dibromomethyl)-3-fluorophenyl]-1,2,4-oxadiazole Chemical compound C1=C(C(Br)Br)C(F)=CC(C2=NOC=N2)=C1 RDRZEPABDVDQAK-UHFFFAOYSA-N 0.000 description 2
• VKRFUGHXKNNIJO-UHFFFAOYSA-N 4,4,4-trifluorobutan-1-ol Chemical compound OCCCC(F)(F)F VKRFUGHXKNNIJO-UHFFFAOYSA-N 0.000 description 2
• ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 2
• AYAIJXOLOYQFPL-UHFFFAOYSA-N 5,5,5-trifluoro-2-(1-phenylethylamino)pentanamide Chemical compound FC(F)(F)CCC(C(N)=O)NC(C)C1=CC=CC=C1 AYAIJXOLOYQFPL-UHFFFAOYSA-N 0.000 description 2
• 208000037259 Amyloid Plaque Diseases 0.000 description 2
• 229910015900 BF3 Inorganic materials 0.000 description 2
• 241000193388 Bacillus thuringiensis Species 0.000 description 2
• 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 2
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 206010015548 Euthanasia Diseases 0.000 description 2
• 108090000698 Formate Dehydrogenases Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 2
• 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 2
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
• 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• 239000012097 Lipofectamine 2000 Substances 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 101000978776 Mus musculus Neurogenic locus notch homolog protein 1 Proteins 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 229910019093 NaOCl Inorganic materials 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 239000004743 Polypropylene Substances 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
• XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
• 150000001413 amino acids Chemical group 0.000 description 2
• 239000000010 aprotic solvent Substances 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• 229940097012 bacillus thuringiensis Drugs 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 239000003610 charcoal Substances 0.000 description 2
• KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
• CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
• 230000000875 corresponding effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 230000008021 deposition Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 229940043279 diisopropylamine Drugs 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 238000006073 displacement reaction Methods 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 230000002183 duodenal effect Effects 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 238000013213 extrapolation Methods 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 239000012065 filter cake Substances 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 239000012737 fresh medium Substances 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 229960002743 glutamine Drugs 0.000 description 2
• 238000005984 hydrogenation reaction Methods 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 239000003999 initiator Substances 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
• 210000004558 lewy body Anatomy 0.000 description 2
• 238000004811 liquid chromatography Methods 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 2
• 238000007431 microscopic evaluation Methods 0.000 description 2
• 210000004897 n-terminal region Anatomy 0.000 description 2
• 208000015122 neurodegenerative disease Diseases 0.000 description 2
• BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
• 239000012299 nitrogen atmosphere Substances 0.000 description 2
• 238000005580 one pot reaction Methods 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
• NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 229920001155 polypropylene Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
• 239000008057 potassium phosphate buffer Substances 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 238000000159 protein binding assay Methods 0.000 description 2
• NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
• 238000003653 radioligand binding assay Methods 0.000 description 2
• 238000001953 recrystallisation Methods 0.000 description 2
• 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
• 238000007363 ring formation reaction Methods 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
• JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
• CRWJEUDFKNYSBX-UHFFFAOYSA-N sodium;hypobromite Chemical compound [Na+].Br[O-] CRWJEUDFKNYSBX-UHFFFAOYSA-N 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000000844 transformation Methods 0.000 description 2
• 102000027257 transmembrane receptors Human genes 0.000 description 2
• 108091008578 transmembrane receptors Proteins 0.000 description 2
• PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• 230000007306 turnover Effects 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
• XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
• AYAIJXOLOYQFPL-MWLCHTKSSA-N (2r)-5,5,5-trifluoro-2-[[(1r)-1-phenylethyl]amino]pentanamide Chemical compound FC(F)(F)CC[C@H](C(N)=O)N[C@H](C)C1=CC=CC=C1 AYAIJXOLOYQFPL-MWLCHTKSSA-N 0.000 description 1
• ZQDLBYQRPAVQKO-VJGNERBWSA-N (2s,3r)-3-(2-methylpropyl)-n'-[(3s)-2-oxo-1-[(3-phenoxyphenyl)methyl]azepan-3-yl]-2-propylbutanediamide Chemical compound O=C1[C@@H](NC(=O)[C@H](CC(C)C)[C@H](CCC)C(N)=O)CCCCN1CC1=CC=CC(OC=2C=CC=CC=2)=C1 ZQDLBYQRPAVQKO-VJGNERBWSA-N 0.000 description 1
• 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
• DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
• 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
• VUZNLSBZRVZGIK-UHFFFAOYSA-N 2,2,6,6-Tetramethyl-1-piperidinol Chemical compound CC1(C)CCCC(C)(C)N1O VUZNLSBZRVZGIK-UHFFFAOYSA-N 0.000 description 1
• XEAOPVUAMONVLA-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N(C(CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-UHFFFAOYSA-N 0.000 description 1
• UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
• GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
• JZTPKAROPNTQQV-UHFFFAOYSA-N 3-fluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1 JZTPKAROPNTQQV-UHFFFAOYSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• XIORGQIMRQZJER-UHFFFAOYSA-N 5,5,5-trifluoropentanamide hydrochloride Chemical compound Cl.NC(=O)CCCC(F)(F)F XIORGQIMRQZJER-UHFFFAOYSA-N 0.000 description 1
• 208000018282 ACys amyloidosis Diseases 0.000 description 1
• WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
• 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• 206010003497 Asphyxia Diseases 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
• VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
• 101100495314 Caenorhabditis elegans cdk-5 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 229940126062 Compound A Drugs 0.000 description 1
• 102000009666 Cytochrome P-450 CYP2B6 Human genes 0.000 description 1
• 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 1
• 102000002263 Cytochrome P-450 CYP2C8 Human genes 0.000 description 1
• 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 1
• 208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• 102000004674 D-amino-acid oxidase Human genes 0.000 description 1
• 108010003989 D-amino-acid oxidase Proteins 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 101100441092 Danio rerio crlf3 gene Proteins 0.000 description 1
• 206010012239 Delusion Diseases 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 1
• 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 206010019075 Hallucination, visual Diseases 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
• 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 1
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
• 101000745711 Homo sapiens Cytochrome P450 3A4 Proteins 0.000 description 1
• 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 101710189714 Major cell-binding factor Proteins 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101000836282 Mus musculus Solute carrier organic anion transporter family member 1C1 Proteins 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• 241000872931 Myoporum sandwicense Species 0.000 description 1
• PHSRRHGYXQCRPU-AWEZNQCLSA-N N-(3-oxododecanoyl)-L-homoserine lactone Chemical compound CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O PHSRRHGYXQCRPU-AWEZNQCLSA-N 0.000 description 1
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
• 238000011887 Necropsy Methods 0.000 description 1
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
• 235000019502 Orange oil Nutrition 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000027089 Parkinsonian disease Diseases 0.000 description 1
• 206010034010 Parkinsonism Diseases 0.000 description 1
• 101000579647 Penaeus vannamei Penaeidin-2a Proteins 0.000 description 1
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 239000004280 Sodium formate Substances 0.000 description 1
• 239000005708 Sodium hypochlorite Substances 0.000 description 1
• 102100027233 Solute carrier organic anion transporter family member 1B1 Human genes 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 238000007059 Strecker synthesis reaction Methods 0.000 description 1
• 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 1
• 101710150875 TAR DNA-binding protein 43 Proteins 0.000 description 1
• 239000007984 Tris EDTA buffer Substances 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 201000004810 Vascular dementia Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 150000003869 acetamides Chemical class 0.000 description 1
• 239000003377 acid catalyst Substances 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 238000005377 adsorption chromatography Methods 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• UVJPCPROJZIFAV-YAUCMBIBSA-N alpha-L-Rhap-(1->3)-[alpha-L-Rhap-(1->3)-beta-D-Glcp-(1->4)]-alpha-D-Glcp-(1->2)-alpha-D-Glcp Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H]1O UVJPCPROJZIFAV-YAUCMBIBSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
• 206010002022 amyloidosis Diseases 0.000 description 1
• 201000002779 amyotrophic lateral sclerosis type 10 Diseases 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 101150089041 aph-1 gene Proteins 0.000 description 1
• 201000007201 aphasia Diseases 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 229940039856 aricept Drugs 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 229960005370 atorvastatin Drugs 0.000 description 1
• 238000011888 autopsy Methods 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 238000007664 blowing Methods 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
• SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 238000012754 cardiac puncture Methods 0.000 description 1
• 201000011529 cardiovascular cancer Diseases 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000012820 cell cycle checkpoint Effects 0.000 description 1
• 239000008004 cell lysis buffer Substances 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 229950001653 cilomilast Drugs 0.000 description 1
• 229960005228 clioquinol Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 238000002784 cytotoxicity assay Methods 0.000 description 1
• 231100000263 cytotoxicity test Toxicity 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 231100000868 delusion Toxicity 0.000 description 1
• 239000002274 desiccant Substances 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• UCQFCFPECQILOL-UHFFFAOYSA-N diethyl hydrogen phosphate Chemical compound CCOP(O)(=O)OCC UCQFCFPECQILOL-UHFFFAOYSA-N 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 229960003530 donepezil Drugs 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 230000008406 drug-drug interaction Effects 0.000 description 1
• 235000021463 dry cake Nutrition 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 150000003883 epothilone derivatives Chemical class 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 239000002834 estrogen receptor modulator Substances 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 229940108366 exelon Drugs 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 125000001207 fluorophenyl group Chemical group 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 229960003980 galantamine Drugs 0.000 description 1
• ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
• 238000007489 histopathology method Methods 0.000 description 1
• 239000011539 homogenization buffer Substances 0.000 description 1
• 102000044284 human CYP3A4 Human genes 0.000 description 1
• 102000046617 human NR1I2 Human genes 0.000 description 1
• XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 239000012216 imaging agent Substances 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 238000003318 immunodepletion Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
• 108010052968 leupeptin Proteins 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 229960004640 memantine Drugs 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 208000023060 memory loss Diseases 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 210000001589 microsome Anatomy 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• ZZKSAVUXOUDMGW-UHFFFAOYSA-N n-(2-methoxyethyl)benzamide Chemical compound COCCNC(=O)C1=CC=CC=C1 ZZKSAVUXOUDMGW-UHFFFAOYSA-N 0.000 description 1
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
• 229940033872 namenda Drugs 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 102000046701 nicastrin Human genes 0.000 description 1
• 108700022821 nicastrin Proteins 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 238000006384 oligomerization reaction Methods 0.000 description 1
• 238000003305 oral gavage Methods 0.000 description 1
• 239000010502 orange oil Substances 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000004783 oxidative metabolism Effects 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 238000001139 pH measurement Methods 0.000 description 1
• 230000020477 pH reduction Effects 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000006201 parenteral dosage form Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 108010091212 pepstatin Proteins 0.000 description 1
• FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 229940117803 phenethylamine Drugs 0.000 description 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000022256 primary systemic amyloidosis Diseases 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 229960003581 pyridoxal Drugs 0.000 description 1
• 235000008164 pyridoxal Nutrition 0.000 description 1
• 239000011674 pyridoxal Substances 0.000 description 1
• 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
• 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
• 229960001327 pyridoxal phosphate Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 229940051845 razadyne Drugs 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 102000027483 retinoid hormone receptors Human genes 0.000 description 1
• 108091008679 retinoid hormone receptors Proteins 0.000 description 1
• 238000010242 retro-orbital bleeding Methods 0.000 description 1
• 229960004136 rivastigmine Drugs 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 238000003118 sandwich ELISA Methods 0.000 description 1
• CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 description 1
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
• 239000000849 selective androgen receptor modulator Substances 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 231100000161 signs of toxicity Toxicity 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
• 235000019254 sodium formate Nutrition 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
• JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 125000005425 toluyl group Chemical group 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 239000003558 transferase inhibitor Substances 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
• 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
• 229950009811 ubenimex Drugs 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 238000005292 vacuum distillation Methods 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 238000010626 work up procedure Methods 0.000 description 1